Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agile Therapeutics, Inc. - Common Stock (NQ: AGRX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agile Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
H.C. Wainwright & Co, reiterated its buy rating on Agile Therapeutics, Inc. (NASDAQ: AGRX) this month, setting a price target of $12 per share. 
Via Benzinga
The Overturning of Roe v. Wade Has Changed the Landscape of Birth Control; Smaller Companies are now an Integral Part of Care
Via ACCESSWIRE
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
Agile Therapeutics (NASDAQ: AGRX) announced the closing of its public offering in May. 
Via Benzinga
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
From Agile Therapeutics, Inc.
Via GlobeNewswire
5 Value Stocks In The Healthcare Sector
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 32 companies set new 52-week lows. 
Via Benzinga
Agile Therapeutics – This Women's Healthcare Company's "Skinfusion" Technology Sets It Apart From Other Contraceptive Companies
Al Altomari, Chairman & CEO of Agile Therapeutics (NASDAQ: AGRX) was recently interviewed by Benzinga.  
Via Benzinga
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
From Agile Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 64 companies achieved new lows for the year. 
Via Benzinga
Why Agile Therapeutics Stock Is Trading Higher Today
Agile Therapeutics Inc (NASDAQ: AGRX) announced an agreement with vitaCare Prescription Services, a wholly owned subsidiary of GoodRx Holdings Inc (NASDAQ: GDRX), to expand patient access and... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Inventiva Shares Are Trading Higher By 24%; Here Are 20 Stocks Moving Premarket
Gainers Cyxtera Technologies, Inc. (NASDAQ: CYXT) shares rose 134.6% to $0.0981 in pre-market trading after dropping 12% on Tuesday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as investors get ready to trade shares on Wednesday morning! 
Via InvestorPlace
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Agile Therapeutics: Q1 Earnings Insights
Via Benzinga
Agile Therapeutics Earnings Preview
Via Benzinga
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 – What Is The Hype All About?
Women are itching for more birth control options that cater to their unique needs and preferences. While traditional forms of birth control – such as the pill and condoms – have been reliable options... 
Via Benzinga
The Overturning of Roe v. Wade Has Changed The Landscape Of Birth Control; Smaller Companies Are Now An Integral Part Of Care
The invention of birth control in the 1960s revolutionized women's health and their lives. In 2022, the contraceptive market was valued at $8.3 billion and it is projected to grow at a compound annual... 
Via Benzinga
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
Live Conference Call and Webcast at 4:30 p.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics: The CEO Of This Women's Healthcare Company That Recently Saw Revenue Growth Of 33% Speaks To Benzinga
Al Altomari, Chairman & CEO of Agile Therapeutics (NASDAQ: AGRX) was recently a guest on Benzinga’s All Access. 
Via Benzinga
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
National Instruments, Nutex Health And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Why Kalera Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 164% to $3.86 after the company announced it launched ChatGPT-enabled smart eyewear. 
Via Benzinga
Agile Therapeutics Announces 1-For-50 Reverse Stock Split
From Agile Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.